Clinical Trial Update: Platinum for Triple-Negative Metastatic Breast Cancer and Evaluation of p63/p73 as a Biomarker of Response [Phase 2]

View source ↗

Summary

This update reports Phase 2 results from a trial of platinum-based chemotherapy in triple-negative metastatic breast cancer and evaluates p63/p73 as biomarkers …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Platinum-based chemotherapy (platinum-based chemotherapy)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-06-01